Vaccine and drug delivery by intranasal application of vector and vector extracts

Abstract

Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response.

1 - 10 . (canceled) 
     
     
         11 . A pharmaceutical dosage for intranasal administration, comprising:
 a pharmaceutical acceptable carrier in a liquid form admixed with a non-replicating adenoviral vector that expresses one or more influenza antigens, one or more influenza epitopes, or a combination thereof, wherein the vector is configured to non-invasively induce a protective immune response against influenza.   
     
     
         12 . The pharmaceutical dosage of  claim 11 , further comprising a squeeze spray dispenser, a pump dispenser, or an aerosol dispenser. 
     
     
         13 . The pharmaceutical dosage of  claim 11 , wherein the adenoviral vector is defective in its E1 and/or E3 and/or E4 regions. 
     
     
         14 . The pharmaceutical dosage of  claim 11 , wherein the adenoviral vector is defective in its E1/E3 region. 
     
     
         15 . The pharmaceutical dosage of  claim 11 , wherein the adenoviral vector is defective in all adenoviral genes. 
     
     
         16 . The pharmaceutical dosage of  claim 11 , further comprising an adjuvant. 
     
     
         17 . The pharmaceutical dosage of  claim 11 , wherein the influenza antigen is influenza hemagglutinin or influenza nuclear protein. 
     
     
         18 . A pharmaceutical dosage for intranasal administration, comprising:
 a pharmaceutical acceptable carrier in a liquid form admixed with a non-replicating adenoviral vector that expresses one or more heterologous antigens of interest, wherein the vector is configured to non-invasively induce a protective immune response against a pathogen.   
     
     
         19 . The pharmaceutical dosage of  claim 18 , wherein the one or more heterologous antigens of interest is selected from the group consisting of influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, rabies glycoprotein, HBV surface antigen, HIV gp120, HIV gp160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg,  botulinum  toxin A and  mycobacterium tuberculosis  HSP. 
     
     
         20 . The pharmaceutical dosage of  claim 18 , further comprising a squeeze spray dispenser, a pump dispenser, or an aerosol dispenser. 
     
     
         21 . The pharmaceutical dosage of  claim 18 , wherein the adenoviral vector is defective in its E1 and/or E3 and/or E4 regions. 
     
     
         22 . The pharmaceutical dosage of  claim 18 , wherein the adenoviral vector is defective in its E1/E3 region. 
     
     
         23 . The pharmaceutical dosage of  claim 18 , wherein the adenoviral vector is defective in all adenoviral genes. 
     
     
         24 . The pharmaceutical dosage of  claim 18 , further comprising an adjuvant. 
     
     
         25 . A pharmaceutical dosage for intranasal administration, comprising:
 a pharmaceutical acceptable carrier in a liquid form admixed with a non-replicating adenoviral vector that expresses one or more heterologous antigens of interest, wherein the vector is configured to non-invasively induce a protective immune response against a pathogen; and,   a dispenser.   
     
     
         26 . The pharmaceutical dosage of  claim 25 , wherein the dispenser is a squeeze spray dispenser, a pump dispenser, or an aerosol dispenser. 
     
     
         27 . The pharmaceutical dosage of  claim 25 , wherein the one or more heterologous antigens of interest is selected from the group consisting of influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, rabies glycoprotein, HBV surface antigen, HIV gp120, HIV gp160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg,  botulinum  toxin A and  mycobacterium tuberculosis  HSP.